Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
This is why I believe Lynparza is massive annual sales will far exceed Tranilast and it will become one of the world leaders
https://www.marketwatch.com/amp/story/svb-leerink-astrazenecas-lynparza-could-bring-in-97-billion-in-sales-by-2028-2022-03-14
Merck to present extended pipeline for 6 drugs including Lynparza at the ASCO meeting in June
https://stockhouse.com/news/press-releases/2022/05/10/merck-to-present-data-at-2022-asco-annual-meeting-highlighting-promising
Also it shows that the counterparty(ies) were wanting to progress discussions further to appoint DG formally.
PS He May be the next CEO if negotiations are concluded favourably might be what AR meant about the appointment progressing well .
Yes Soup agree, in isolation it could be read as picking up where DG previously left off ie going back to past contacts however also with DGs comment regarding formalising his role it is clear they were referring to current discussions already underway and before 2/3.
This caught my attention from the RNS 2/3 DG said
“My detailed knowledge of previous development strategies, commercial discussions and continued commitment to the success of the project and the Company will now be brought to bear in a formal way, ”
Does that mean he had provided some informal guidance and it had reached a level that it had to become commercial.
Tranilast to gain substantial traction 2026
https://news.marketsizeforecasters.com/tranilast-market-208186
“The competitive landscape of the Tranilast market is defined by key players such as BioChemPartner,CarboMer,Cayman Chemical,AOBIOUS,MANUS AKTTEVA BIOPHARMA,FUJIFILM Wako Pure Chemical Corporation,Enzo Life Sciences,Adooq Bioscience,LGM Pharma andDaiwa Pharmaceutical.”
https://news.marketsizeforecasters.com/tranilast-market-208186
Sorry Soup quite right incorrect phraseology just a bit knackered from a family trauma. Meant US patent office srticle attached
https://pharmaphorum.com/news/biogen-protects-tecfidera-1-25bn-deal-forward/
Interesting position to be in from the Trifecdora Biogen eg they did not take the risk waiting for the patent from them he FDA however it did affect the terms which were then enhanced with the FDA outcome. We have a precedent with NXP002 where the FDA have issued a similar patent.if the Bod have said you have first refusal then we will have to wait as AZ will not need to rush, however given recent FDA approvals any US pharma will put pressure on AZ.
Merck announced record results, with Keytruda being its main drug at $4.8bn. Forecasts suggest Lynparza will overtake this figure.
https://www.fitchsolutions.com/pharma-healthcare/merck-co-raises-guidance-back-stellar-q122-results-03-05-2022?amp